For research use only. Not for therapeutic Use.
Motesanib (Cat.No:I003594) is a small molecule tyrosine kinase inhibitor that targets multiple receptors involved in tumor angiogenesis and growth, including VEGFR, PDGFR, and c-Kit. It has shown potential in the treatment of various cancers, particularly advanced thyroid cancer. Motesanib works by inhibiting the signaling pathways involved in tumor cell proliferation and angiogenesis, offering a therapeutic approach for certain malignancies.
Catalog Number | I003594 |
CAS Number | 453562-69-1 |
Synonyms | N-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide |
Molecular Formula | C₂₂H₂₃N₅O |
Purity | ≥95% |
Target | c-Kit |
Solubility | 10 mM in DMSO |
Storage | Store at -20°C |
IC50 | 2 nM/3 nM/6 nM/8 nM(VEGFR1/2/3/c-Kit) [1] |
IUPAC Name | N-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide |
InChI | InChI=1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28) |
InChIKey | RAHBGWKEPAQNFF-UHFFFAOYSA-N |
SMILES | CC1(CNC2=C1C=CC(=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4)C |
Reference | <p style=/line-height:25px/> |